A temporal validation study evaluating the predictive clinical score known as HADES has reproduced the discriminative performance of its original derivation model in identifying patients with suspected hereditary angioedema due to C1 inhibitor deficiency. Researchers observed an area under the receiver operating characteristic curve of 0.80, with a 95 percent confidence interval spanning from 0.73 to 0.86, matching the diagnostic performance documented in the initial derivation dataset.
Hereditary angioedema due to C1 inhibitor deficiency, designated as HAE-C1-INH, is frequently misdiagnosed in clinical settings, a problem that leads to delayed diagnosis and inappropriate clinical management. To address these diagnostic delays, investigators previously developed the HADES clinical scoring system as a predictive mechanism designed to support the early identification of individuals at risk for the condition.
To assess the temporal performance of the predictive score and explore the practical feasibility of digital delivery, the researchers evaluated a new cohort comprising 539 individuals presenting with suspicion of HAE-C1-INH. Numerical HADES scores were calculated for all participants in the validation cohort using previously predefined score thresholds to ensure standardized comparison with the derivation dataset.
The validation cohort successfully reproduced the key performance characteristics identified during the development of the scoring tool. Sensitivity remained at 100 percent when evaluated at low score thresholds, while diagnostic specificity demonstrated a progressive increase across higher score categories. Furthermore, the analysis confirmed that zero confirmed cases of HAE-C1-INH occurred within score category 0.
In parallel with the primary cohort analysis, the investigators conducted a prospective pilot study involving 18 patients to evaluate the implementation feasibility of a mobile digital platform designated as the HADES App. This exploratory digital cohort generated preliminary observational information regarding the feasibility of deploying the predictive scoring algorithm within clinical workflows.
In addition, six patients with HAE-FXII were analyzed separately for exploratory purposes. Analysis of this subgroup revealed that individuals with HAE-FXII displayed clinical score distributions that overlapped with the score distributions observed among confirmed HAE-C1-INH cases.
The authors concluded that the temporal validation cohort confirms discriminative performance consistent with the original study and provides reasonable overall category-level calibration. These findings support the potential role of HADES as a clinical screening tool for HAE-C1-INH, while indicating that preliminary findings from the digital application warrant further prospective evaluation.
Subject of Research: Temporal validation and digital app implementation of the HADES predictive score for hereditary angioedema
Article Title: Validation and digital implementation of the HADES score for hereditary angioedema
Article References: Zwiener, R. D., Castro Labrador, L., Zamora, R., Galmarini, C. M., Brion, L., Pino, A., & Rozenfeld, P. (2026). Validation and digital implementation of the HADES score for hereditary angioedema. Frontiers in Epidemiology, 6, 2000978. https://doi.org/10.3389/fepid.2026.2000978
Image Credits: AI Generated
DOI: 10.3389/fepid.2026.2000978
Keywords: Hereditary angioedema, HAE-C1-INH, HADES score, Clinical screening tool, Predictive clinical score, Temporal validation cohort, ROC analysis, Area under the curve, Diagnostic performance, Clinical decision support, Digital health implementation, HADES App, HAE-FXII, C1 inhibitor deficiency, Clinical epidemiology, Sensitivity and specificity
News Source: Ophelia Keating. (November 12, 2026). HADES Clinical Score Demonstrates Consistent Discriminative Accuracy for Hereditary Angioedema Screening. Scienmag.



